0001209191-17-048408.txt : 20170810 0001209191-17-048408.hdr.sgml : 20170810 20170810160610 ACCESSION NUMBER: 0001209191-17-048408 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170809 FILED AS OF DATE: 20170810 DATE AS OF CHANGE: 20170810 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Daly David CENTRAL INDEX KEY: 0001320267 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36086 FILM NUMBER: 171021503 MAIL ADDRESS: STREET 1: 33171 PASEO CERVEZA CITY: SAN JUAN CAPISTRANO STATE: CA ZIP: 92675 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Foundation Medicine, Inc. CENTRAL INDEX KEY: 0001488613 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 271316416 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 150 SECOND STREET CITY: CAMBRIDGE STATE: MA ZIP: 02141 BUSINESS PHONE: 617-418-2200 MAIL ADDRESS: STREET 1: 150 SECOND STREET CITY: CAMBRIDGE STATE: MA ZIP: 02141 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2017-08-09 0 0001488613 Foundation Medicine, Inc. FMI 0001320267 Daly David C/O FOUNDATION MEDICINE, INC. 150 SECOND STREET CAMBRIDGE MA 02141 0 1 0 0 Chief Commercial Officer Common Stock 2017-08-09 4 M 0 46872 22.24 A 163133 D Common Stock 2017-08-09 4 S 0 46872 39.50 D 116261 D Stock Option (right to buy) 22.24 2017-08-09 4 M 0 46872 0.00 D 2024-12-05 Common Stock 46872 28128 D The price reported in this Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $39.05 to $40.25, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote. This option was granted on December 5, 2014 and is exercisable (i) with respect to 25% of the shares subject to the options, on November 30, 2015, and (ii) with respect to 6.25% of the shares subject to the option, on each subsequent three month period beginning February 28, 2016 until fully vested. /s/ Robert W. Hesslein, as Attorney-in-Fact for David Daly 2017-08-10